Company / Interest Expense
Outlook Therapeutics, Inc. Interest Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
-$3.2M
FY2025
5-year range
-$3.2M / $5.6M
FY2021-FY2025
Trend
-191.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Interest Expense has declined for 3 consecutive years, from $6M in FY2018 to -$3M in FY2025.
Based on SEC 10-K filings.
-$3M in FY2025.
Improved from $4M to -$3M over the past 6 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Outlook Therapeutics, Inc.'s interest expense has declined for 3 consecutive years.
- In FY2025, interest expense decreased 191.1% year-over-year.
- Peak interest expense was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.2M | -191.1% |
| FY2020 | $3.5M | -10.9% |
| FY2019 | $3.9M | -30.8% |
| FY2018 | $5.6M | +203.8% |
| FY2017 | $1.9M | -19.4% |
| FY2016 | $2.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026